Get the Stockscreener App
25.70
1.54%
0.375
Pulse Biosciences Inc stock is traded at $25.70, with a volume of 59,895.
It is up +1.54% in the last 24 hours and up +34.80% over the past month.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
See More
Previous Close:
$25.33
Open:
$25.59
24h Volume:
59,895
Relative Volume:
0.20
Market Cap:
$1.78B
Revenue:
$751.00K
Net Income/Loss:
$-74.57M
P/E Ratio:
-23.30
EPS:
-1.1031
Net Cash Flow:
$-54.46M
1W Performance:
+4.26%
1M Performance:
+34.80%
6M Performance:
+90.66%
1Y Performance:
+50.41%
1-Day Range:
$25.30
$26.30
1-Week Range:
$23.60
$28.53
52-Week Range:
$12.56
$28.53
Pulse Biosciences Inc Stock (PLSE) Company Profile
Name
Pulse Biosciences Inc
Sector
Industry
Phone
510-906-4600
Address
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, ALC, RMD, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
25.70 | 1.75B | 751.00K | -74.57M | -54.46M | -1.1031 |
ISRG
Intuitive Surgical Inc
|
419.79 | 149.48B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
149.21 | 41.65B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
66.55 | 32.58B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
193.85 | 28.44B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
33.24 | 28.42B | 29.14B | 1.07B | 1.05B | 1.1956 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | Mizuho | Outperform |
| Jul-07-25 | Initiated | Oppenheimer | Outperform |
| Jul-27-21 | Initiated | Stephens | Overweight |
| Mar-11-21 | Initiated | Maxim Group | Buy |
| Jan-26-21 | Reiterated | H.C. Wainwright | Buy |
| May-12-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-14-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-25-19 | Initiated | H.C. Wainwright | Buy |
View All
Pulse Biosciences Inc Stock (PLSE) Latest News
Does Pulse Biosciences’ (PLSE) Insider Buying Reinforce Canaccord’s Cardiac PFA Thesis or Raise New Questions? - Sahm
Pulse Biosciences board approves affiliate participation in equity sales program - Investing.com
Pulse Biosciences (PLSE) Initiated with Buy Rating and $32 Targe - GuruFocus
Canaccord initiates Pulse Biosciences stock with buy on ablation tech - Investing.com UK
PLSE Initiates Coverage On by Canaccord Genuity -- Price Target Set at $32 - GuruFocus
Canaccord initiates Pulse Biosciences stock with buy on ablation tech By Investing.com - Investing.com Nigeria
Canaccord Genuity Initiates Pulse Biosciences at Buy With $32 Price Target - marketscreener.com
CCORF Initiates Pulse Biosciences(PLSE.US) With Buy Rating, Announces Target Price $32 - Moomoo
Here's why Pulse Biosciences, Inc (PLSE) is a great momentum stock to buy - MSN
Discipline and Rules-Based Execution in PLSE Response - Stock Traders Daily
PLSE Technical Analysis & Stock Price Forecast - Intellectia AI
PLSE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Pulse Biosciences (PLSE) Valuation Check After Strong Recent Share Price Momentum - Sahm
PLSE Q1 2026 Earnings: EPS Beat but No Revenue as Stock DeclinesEarnings Miss Alert - thelegaladvocate.com
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 - BioSpace
Pulse Biosciences (PLSE) Holds Steady: Key Levels in FocusButterfly Setup - The Legal Advocate
Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy - Yahoo Finance
Pulse Biosciences Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Pulse Biosciences (PLSE) Rises Modestly as Shares Test Key ResistanceTICK Divergence - The Legal Advocate
Assessing Pulse Biosciences (PLSE) Valuation After Recent Share Price Surge - Sahm
Pulse Biosciences Begins nPulse Study for Malignant Thyroid Tumor Treatment - Medical Product Outsourcing
Pulse Biosciences Earnings Call Highlights Clinical Momentum - TipRanks
Behavioral Patterns of PLSE and Institutional Flows - Stock Traders Daily
Pulse Biosciences, IncCommon Stock (NQ: PLSE - The Chronicle-Journal
PLSE accelerates cardiac catheter program after breakthrough AFib data - MSN
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors. - The Globe and Mail
Pulse Biosciences CEO Buys 15,000 Shares: SEC Filing Details | May 2026News and Statistics - IndexBox
(SEC Amendment) Pulse Biosciences(PLSE.US) 10% Shareholder Buys US$13 Million in Common Stock - Moomoo
Pulse Biosciences director Robert W. Duggan acquires $13m in stock - Investing.com Nigeria
Pulse Biosciences director Robert W. Duggan acquires $13m in stock By Investing.com - Investing.com South Africa
Director Robert Duggan buys 660K Pulse Biosciences (PLSE) shares - Stock Titan
Pulse Bio rises after over $13M insider buying - MSN
Pulse Biosciences stock hits 52-week high at 26.33 USD By Investing.com - Investing.com Nigeria
Pulse Biosciences, Inc. Q1 2026 Financial Report – Revenue, Losses, and Key Corporate Updates - Minichart
Pulse Biosciences Announces Clinical Data From nPulse Vybrance System Study - Medical Product Outsourcing
Pulse Biosciences stock hits 52-week high at 26.33 USD - Investing.com India
Pulse Biosciences stock (US73242P1030): Q1 2026 net loss widens to $18.6M on early commercialization - AD HOC NEWS
PULSE BIOSCIENCES, INC. 1Q 2026: Revenue $401K, EPS ($0.27) — 10-Q Summary - TradingView
Pulse Biosciences (NASDAQ: PLSE) Q1 2026 results, cash burn and AF strategy - Stock Titan
Pulse Biosciences, Inc. (PLSE) Presents at Bank of America Global Healthcare Conference 2026Slideshow - Seeking Alpha
[SCHEDULE 13D/A] PULSE BIOSCIENCES, INC. Amended Major Shareholder Report - Stock Titan
Pulse Biosciences Insider Bought Shares Worth $12,999,988, According to a Recent SEC Filing - Moomoo
Pulse Biosciences Inc Stock (PLSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pulse Biosciences Inc Stock (PLSE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Director |
May 11 '26 |
Buy |
19.69 |
660,233 |
12,999,988 |
48,211,433 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Option Exercise |
1.53 |
5,000 |
7,650 |
48,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Sale |
23.64 |
5,000 |
118,200 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Sale |
23.63 |
20,000 |
472,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Sale |
23.53 |
20,000 |
470,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Sale |
23.37 |
20,000 |
467,400 |
43,298 |
0.09%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):